Yan Yan

Yan Yan

Auto-generated profile, based on publicly available information

Yan Yan

Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ASAnupriya Singhal
Anupriya Singhal
HSHannah C. Styers
Hannah C. Styers
JRJonathan Rub
Jonathan Rub
ZLZhuxuan Li
Zhuxuan Li
STStefan Torborg
Stefan Torborg
TTTuomas Tammela
Tuomas Tammela
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor–induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state–directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer. Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy. See related commentary by Marasco and Misale, p. 2018

6 November 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZLZhuxuan Li
Zhuxuan Li
XZXueqian Zhuang
Xueqian Zhuang
CPChun-Hao Pan
Chun-Hao Pan
YYYan Yan
Yan Yan
RTRohit Thummalapalli
Rohit Thummalapalli
TTTuomas Tammela
Tuomas Tammela
Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but the clinical benefit is limited by intrinsic and acquired resistance. LUAD predominantly arises from alveolar type 2 (AT2) cells, which function as facultative alveolar stem cells by self-renewing and replacing alveolar type 1 (AT1) cells. Using genetically engineered mouse models, patient-derived xenografts, and patient samples, we found inhibition of KRAS promotes transition to a quiescent AT1-like cancer cell state in LUAD tumors. Similarly, suppressing Kras induced AT1 differentiation of wild-type AT2 cells upon lung injury. The AT1-like LUAD cells exhibited high growth and differentiation potential upon treatment cessation, whereas ablation of the AT1-like cells robustly improved treatment response to KRAS inhibitors. Our results uncover an unexpected role for KRAS in promoting intratumoral heterogeneity and suggest that targeting alveolar differentiation may augment KRAS-targeted therapies in LUAD. Significance: Treatment resistance limits response to KRAS inhibitors in LUAD patients. We find LUAD residual disease following KRAS targeting is composed of AT1-like cancer cells with the capacity to reignite tumorigenesis. Targeting the AT1-like cells augments responses to KRAS inhibition, elucidating a therapeutic strategy to overcome resistance to KRAS-targeted therapy. This article is featured in Selected Articles from This Issue, p. 201

21 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
JCJason E. Chan
Jason E. Chan
CPChun-Hao Pan
Chun-Hao Pan
JRJonathan Rub
Jonathan Rub
GGGary Guzman
Gary Guzman
KKKlavdija Krause
Klavdija Krause
TTTuomas Tammela
Tuomas Tammela
Plasticity—the ability of cells to undergo phenotypic transitions—drives cancer progression and therapy resistance1,2,3. Recent studies have suggested that plasticity in solid tumours is concentrated in a minority subset of cancer cells4,5,6, yet functional studies examining this high-plasticity cell state (HPCS) in situ are lacking. Here we develop mouse models enabling the detection, longitudinal lineage tracing and ablation of the HPCS in autochthonous lung tumours in vivo. Lineage tracing reveals that the HPCS cells possess a high capacity for cell state transitions, giving rise to both early neoplastic (differentiated) and progressed lung cancer cell states in situ. Longitudinal lineage tracing using secreted luciferases reveals that HPCS-derived cells have a high capacity for growth compared with bulk cancer cells or another cancer cell state with features of differentiated lung epithelium. Ablation of HPCS cells in early neoplasias abrogates benign-to-malignant transition, whereas ablation in established tumours by suicide gene or chimeric antigen receptor (CAR) T cells robustly reduces tumour burden. We further demonstrate that the HPCS gives rise to therapy-resistant cell states, whereas HPCS ablation suppresses resistance to chemotherapy and oncoprotein-targeted therapy. Notably, an HPCS-like state is ubiquitous in regenerating epithelia and in carcinomas of multiple other tissues, revealing a convergence of plasticity programs. Our work establishes the HPCS as a critical hub enabling reciprocal transitions between cancer cell states. Targeting the HPCS in lung cancer and in other carcinomas may suppress cancer progression and eradicate treatment resistance.

27 August 2022 in Arabian Journal of Geosciences
Verified
Journal Article
Closed access
PDF file
FXFang Xiao
Fang Xiao
YZYan-feng Zhuang
Yan-feng Zhuang
YLYani Liu
Yani Liu
YYYan Yan
Yan Yan

8 February 2024
Verified
Other
Open access
ZLZhuxuan Li
Zhuxuan Li
XZXueqian Zhuang
Xueqian Zhuang
CPChun-Hao Pan
Chun-Hao Pan
YYYan Yan
Yan Yan
RTRohit Thummalapalli
Rohit Thummalapalli
TTTuomas Tammela
Tuomas Tammela
Supplementary Table 6 shows the TotalSeqB hashtag oligonucleotide-conjugated antibodies.

8 February 2024
Verified
Other
Open access
ZLZhuxuan Li
Zhuxuan Li
XZXueqian Zhuang
Xueqian Zhuang
CPChun-Hao Pan
Chun-Hao Pan
YYYan Yan
Yan Yan
RTRohit Thummalapalli
Rohit Thummalapalli
TTTuomas Tammela
Tuomas Tammela
Supplementary Table 5 shows the primers used in this study.